McKesson Corporation

McKesson Corporation

MCKNYSE / NASDAQHealthcareLarge cap

$1,069.43+$7.27 (+0.7%)

Last close · Data as of Nov 20, 2026

Market cap
$91.0B
P/E
19.1x
EV / EBITDA
13.3x
Revenue
$403.4B
Net margin
1.2%
ROCE
42.2%

+25.9% over the last year

McKesson Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+3.8%
3M
+27.5%
6M
+41.7%
1Y
+25.9%
5Y
+384.1%

52-week range

Day change +$7.27 (+0.7%) from $1,062 to $1,069 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in MCK, bought on each weekday since 2021.

News & filings

What McKesson filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Return on capital employed of 42.2%.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2026

Rule-based from financial data. Not advice.

About the company

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

Read moreShow less

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners to address challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver solutions to help people get the medicine needed to live healthier lives; and provides medication access and affordability, prescription decision support, prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services, as well as electronic prior authorization services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, biomedical maintenance, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, post-acute care facilities, hospital reference labs, and home health care agencies. The International segment delivers medicines, supplies, and information technology solutions to retail pharmacies, hospitals, long-term care centers, clinics and institutions; and provides logistics and distribution services for manufacturers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Sector
Healthcare
Shares outstanding
123.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$91.0B
P/E
19.1x
P/B
-41.9x
EV / EBITDA
13.3x
EV / Sales
0.2x
P/S
0.2x
52-week high
$1,105.04
52-week low
$725.17

Profitability

Operating margin
1.6%
Net margin
1.2%
EBITDA margin
1.8%
ROE
-219.2%
ROCE
42.2%
ROA
5.8%
Asset turnover
4.90

Growth

Revenue
$403.4B
Revenue growth, 1Y
12.4%
Revenue CAGR, 3Y
13.4%
Net profit growth, 1Y
44.5%
Free cash flow
$5.4B

Solvency

Current ratio
0.85
Debt / Equity
-3.97
Debt / Assets
0.10
CFO / Net profit
1.29
Cash / Market cap
4.4%

Where the revenue went

Of every $100 of FY2026 revenue, $1 was left as net income.

McKesson Corporation income statement flow, FY2026
McKesson Corporation income statement flow, FY2026: flows
FromToAmount
RevenueCost of revenue$388.9B
RevenueGross profit$14.6B
Gross profitSelling, general and administrative$8.1B
Gross profitOperating income$6.5B
Operating incomePretax income$6.2B
Operating incomeInterest and other expense$253.0M
Pretax incomeTax and other$1.4B
Pretax incomeNet income$4.8B

Revenue and net profit

Revenue grew 12.4% in FY2026; net profit is the dashed line.

McKesson Corporation revenue and net profit by fiscal year
McKesson Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2023$276.7B$3.6B
FY2024$309.0B$3.0B
FY2025$359.1B$3.3B
FY2026$403.4B$4.8B

Cash flows

FY2026: $6.2B from operations, $5.4B free after investment (dashed).

McKesson Corporation operating and free cash flow by fiscal year
McKesson Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2023$5.2B$4.6B
FY2024$4.3B$3.6B
FY2025$6.1B$5.2B
FY2026$6.2B$5.4B

Growth

Latest fiscal year 2026: each figure with its change over the year before.

Revenue
$403.4B+12.4%1Y
EBITDA
$7.2B+36.4%1Y
Net profit
$4.8B+44.5%1Y
Cash from operations
$6.2B+1.2%1Y
Free cash flow
$5.4B+3.5%1Y
Revenue CAGR, 3Y
13.4%
Net profit CAGR, 3Y
10.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2026$403.4B$7.2B$4.8B$5.4B-219.2%+12.4%+44.5%

Monthly returns

Month-by-month returns of MCK across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2026.

LineFY2026
Assets$82.3B
Liabilities$83.2B
Equity-$834.0M
Paid-in capital$8.3B
Retained earnings$22.3B
Treasury stock$32.0B
Minority interest$1.3B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; MCK highlighted.

P/E against peers

MCK trades at 19.1x earnings against a peer median of 19.5x.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
McKesson CorporationMCKthis company$91.0B19.1x-41.9x-219.2%13.3x
Bristol-Myers Squibb CompanyBMY$115.6B16.4x6.3x38.2%10.0x
Stryker CorporationSYK$115.5B35.6x5.2x14.5%20.2x
Vertex Pharmaceuticals IncorporatedVRTX$112.1B28.4x6.0x21.2%22.4x
Medtronic plcMDT$105.2B22.6x2.2x9.7%14.3x
Elevance Health, Inc.ELV$88.9B15.7x2.0x12.9%—
HCA Healthcare, Inc.HCA$80.3B11.8x-13.3x-112.6%8.2x
The Cigna GroupCI$74.2B12.5x1.8x14.3%10.2x
Boston Scientific CorporationBSX$72.6B25.1x3.0x12.0%16.1x
Peer median—19.5x2.6x13.6%14.3x

Year-to-date ROI

MCK since 1 January, against earlier years.

Historical volatility

MCK's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

McKesson Corporation operating margin by fiscal year
McKesson Corporation operating margin by fiscal year
DateOperating margin
FY20231.7%
FY20241.4%
FY20251.3%
FY20261.6%
LineFY2026
Cost of revenueCost Of Revenue$388.9B
Gross profitGross Profit$14.6B
Operating expensesOperating Expense$8.1B
Selling, general and administrativeSelling General And Administration$8.1B
Total expensesTotal Expenses$397.0B
Pretax incomePretax Income$6.2B

Learn while you research

Academy chapters picked for McKesson Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →